Recent Updates
Recently added Catalysts
MNKD Positive Sentiment

MannKind Announces Settlement of Convertible Senior Notes

Thursday, March 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MannKind Corporation announced the successful settlement of $36.3 million in 2.50% convertible senior notes, all of which were converted prior to the maturity date. The settlement, completed on March 4, 2026, included $35.5 million in cash and the issuance of 569,023 shares of common stock. This step reflects MannKind's continued commitment to its financial obligations and its ongoing focus on addressing critical healthcare needs in cardiometabolic and orphan lung diseases.
Price reaction · baseline $2.95 (2026-03-04 close) · hit after-hours · 1 other MNKD headline(s) in the window, move may be shared
day 0 close · peak
-4.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Settlement of $36.3 million in convertible senior notes demonstrates financial stability.
  • Conversion involved both cash and stock, indicating positive shareholder engagement.
  • MannKind continues to focus on transforming chronic disease care with innovative solutions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.2%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Technosphere Insulin
Phase 1 · Healthy Volunteers

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock.
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
MANNKIND is a registered trademark of MannKind Corporation.

Frequently Asked Questions

What did MannKind Corporation announce on March 5, 2026?

MannKind Corporation announced the settlement of $36.3 million in convertible senior notes.

How was the settlement made for the senior notes?

The settlement was made with $35.5 million in cash and 569,023 shares of common stock.

What diseases does MannKind focus on treating?

MannKind focuses on cardiometabolic and orphan lung diseases, including diabetes and heart failure.

What is MannKind's approach to drug development?

MannKind develops innovative drug-device combinations tailored to fit patients' daily lives.

Where can I learn more about MannKind Corporation?

More information can be found on their website at mannkindcorp.com.

ShareAdd on Google
Tags: MNKD Viatris Investor Conferences Healthcare MannKind convertible notes biopharmaceutical chronic disease
Last updated: Mar 5, 2026

Biotech snapshot

Cash runway
$111M liquidity · $6M/mo burn
~18 mo
Low dilution risk
Lead asset
Technosphere InsulinPhase 1
Healthy Volunteers →

Catalyst track record

+93%
best trade around MNKD's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for MNKD.

See every catalyst's timing & PoA →